The ocular administration of such dosage forms is not only uncomfortable for the patient but also of limited efficacy. Despite a large variety of submicron-sized colloidal carriers in the ophthalmic drug delivery field, nanoparticles and liposomes attract most of the attention since they appear to have the potential to yield greater efficacy over existing formulations [12, 13]. Inhibitors,research,lifescience,medical In the last decade, oil-in-water-type lipid emulsions, primarily intended for parenteral applications, have been investigated and are now being exploited as a vehicle to improve the ocular bioavailability of lipophilic drugs [14, 15]. Among these, nanoemulsions are considered excellent alternative
formulations to deliver lipophilic drug substances to the eye. Emulsions provide a high encapsulation rate, an enhanced stability of the active ingredient, and enhanced ocular penetration. The first marketed ophthalmic emulsion drug product was Restasis (Allergan), a preservative-free anionic Inhibitors,research,lifescience,medical emulsion of cyclosporine A (CsA) at 0.05% indicated to increase Inhibitors,research,lifescience,medical tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation. Although approved by FDA in 2002, Restasis was
never accepted by European authorities. Other emulsion-based eye drops available on the US market are artificial tears Inhibitors,research,lifescience,medical (Soothe (Bausch & Lomb) and Refresh Endura (Allergan)). Other ophthalmic nanoemulsions are under development and among them are the products resulting from the Novasorb technology, originated
from work at the Hebrew University of Jerusalem by Professor Simon Benita and developed by the French pharmaceutical company Novagali Pharma. The Novasorb technology platform is based on the cationic nanoemulsion approach. The overall Novasorb strategy exploits the fact that the corneal and conjunctival cells and the mucus layer of glycosyl amino glycans lining the ocular surface are negatively charged at a physiological pH . When applying a positively charged formulation to the eye it is likely that an Inhibitors,research,lifescience,medical electrostatic attraction will occur prolonging the residence time of the formulation on the ocular surface (Figure 1). In addition, the nanosize of the oil droplets creates a huge contact surface with the ocular surface cells enabling Montelukast Sodium enhanced absorption. This approach was primarily conceived for oral administration  and it was adapted a few years later to ocular delivery by Klang et al.  to deliver indomethacin and Abdulrazik and coworkers  who intended to deliver cyclosporine A. Figure 1 Cationic nanoemulsion interacting with negatively charged corneal cells. The effects of the cationic emulsion are (1) to bring lipids to MG-132 in vitro stabilize the tear film, (2) to interact electrostatically with mucins, and (3) to improve ocular absorption.